In vivo structure - Activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors

Jijun Hao, Joshua N. Ho, Jana A. Lewis, Kaleh A. Karim, R. Nathan Daniels, Patrick R. Gentry, Corey R. Hopkins, Craig W. Lindsley, Charles C. Hong

Research output: Contribution to journalArticle

225 Citations (Scopus)

Abstract

The therapeutic potential of small molecule signaling inhibitors is often limited by off-target effects. Recently, in a screen for compounds that perturb the zebrafish embryonic dorsoventral axis, we identified dorsomorphin, the first selective inhibitor of bone morphogenetic protein (BMP) signaling. Here we show that dorsomorphin has significant "off-target" effects against the VEGF (vascular endothelial growth factor) type-2 receptor (Flk1/KDR) and disrupts zebrafish angiogenesis. Since both BMP and VEGF signals are known to be involved in vascular development, we sought to determine whether dorsomorphin's antiangiogenic effects are due to its impact on the BMP or VEGF signals through the development of analogues that target BMP but not VEGF signaling and vice versa. In a structure-activity relationship (SAR) study of dorsomorphin analogues based primarily on their effects on live zebrafish embryos, we identified highly selective and potent BMP inhibitors as well as selective VEGF inhibitors. One of the BMP inhibitors, DMH1, which exclusively targets the BMP but not the VEGF pathway, dorsalized the embryonic axis without disrupting the angiogenic process, demonstrating that BMP signaling was not involved in the angiogenic process. This is one of the first full-scale SAR studies performed in vertebrates and demonstrates the potential of zebrafish as an attractive complementary platform for drug development that incorporates an assessment of in vivo bioactivity and selectivity in the context of a living organism.

Original languageEnglish (US)
Pages (from-to)245-253
Number of pages9
JournalACS Chemical Biology
Volume5
Issue number2
DOIs
StatePublished - Feb 19 2010

Fingerprint

Bone Morphogenetic Proteins
Structure-Activity Relationship
Vascular Endothelial Growth Factor A
Zebrafish
Vascular Endothelial Growth Factor Receptor-2
(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine
Bioactivity
Blood Vessels
Vertebrates
Embryonic Structures
Molecules

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine

Cite this

Hao, J., Ho, J. N., Lewis, J. A., Karim, K. A., Daniels, R. N., Gentry, P. R., ... Hong, C. C. (2010). In vivo structure - Activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors. ACS Chemical Biology, 5(2), 245-253. https://doi.org/10.1021/cb9002865

In vivo structure - Activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors. / Hao, Jijun; Ho, Joshua N.; Lewis, Jana A.; Karim, Kaleh A.; Daniels, R. Nathan; Gentry, Patrick R.; Hopkins, Corey R.; Lindsley, Craig W.; Hong, Charles C.

In: ACS Chemical Biology, Vol. 5, No. 2, 19.02.2010, p. 245-253.

Research output: Contribution to journalArticle

Hao, J, Ho, JN, Lewis, JA, Karim, KA, Daniels, RN, Gentry, PR, Hopkins, CR, Lindsley, CW & Hong, CC 2010, 'In vivo structure - Activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors', ACS Chemical Biology, vol. 5, no. 2, pp. 245-253. https://doi.org/10.1021/cb9002865
Hao, Jijun ; Ho, Joshua N. ; Lewis, Jana A. ; Karim, Kaleh A. ; Daniels, R. Nathan ; Gentry, Patrick R. ; Hopkins, Corey R. ; Lindsley, Craig W. ; Hong, Charles C. / In vivo structure - Activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors. In: ACS Chemical Biology. 2010 ; Vol. 5, No. 2. pp. 245-253.
@article{ffc58968ba334485886b9f29bc2f74c8,
title = "In vivo structure - Activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors",
abstract = "The therapeutic potential of small molecule signaling inhibitors is often limited by off-target effects. Recently, in a screen for compounds that perturb the zebrafish embryonic dorsoventral axis, we identified dorsomorphin, the first selective inhibitor of bone morphogenetic protein (BMP) signaling. Here we show that dorsomorphin has significant {"}off-target{"} effects against the VEGF (vascular endothelial growth factor) type-2 receptor (Flk1/KDR) and disrupts zebrafish angiogenesis. Since both BMP and VEGF signals are known to be involved in vascular development, we sought to determine whether dorsomorphin's antiangiogenic effects are due to its impact on the BMP or VEGF signals through the development of analogues that target BMP but not VEGF signaling and vice versa. In a structure-activity relationship (SAR) study of dorsomorphin analogues based primarily on their effects on live zebrafish embryos, we identified highly selective and potent BMP inhibitors as well as selective VEGF inhibitors. One of the BMP inhibitors, DMH1, which exclusively targets the BMP but not the VEGF pathway, dorsalized the embryonic axis without disrupting the angiogenic process, demonstrating that BMP signaling was not involved in the angiogenic process. This is one of the first full-scale SAR studies performed in vertebrates and demonstrates the potential of zebrafish as an attractive complementary platform for drug development that incorporates an assessment of in vivo bioactivity and selectivity in the context of a living organism.",
author = "Jijun Hao and Ho, {Joshua N.} and Lewis, {Jana A.} and Karim, {Kaleh A.} and Daniels, {R. Nathan} and Gentry, {Patrick R.} and Hopkins, {Corey R.} and Lindsley, {Craig W.} and Hong, {Charles C.}",
year = "2010",
month = "2",
day = "19",
doi = "10.1021/cb9002865",
language = "English (US)",
volume = "5",
pages = "245--253",
journal = "ACS Chemical Biology",
issn = "1554-8929",
publisher = "American Chemical Society",
number = "2",

}

TY - JOUR

T1 - In vivo structure - Activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors

AU - Hao, Jijun

AU - Ho, Joshua N.

AU - Lewis, Jana A.

AU - Karim, Kaleh A.

AU - Daniels, R. Nathan

AU - Gentry, Patrick R.

AU - Hopkins, Corey R.

AU - Lindsley, Craig W.

AU - Hong, Charles C.

PY - 2010/2/19

Y1 - 2010/2/19

N2 - The therapeutic potential of small molecule signaling inhibitors is often limited by off-target effects. Recently, in a screen for compounds that perturb the zebrafish embryonic dorsoventral axis, we identified dorsomorphin, the first selective inhibitor of bone morphogenetic protein (BMP) signaling. Here we show that dorsomorphin has significant "off-target" effects against the VEGF (vascular endothelial growth factor) type-2 receptor (Flk1/KDR) and disrupts zebrafish angiogenesis. Since both BMP and VEGF signals are known to be involved in vascular development, we sought to determine whether dorsomorphin's antiangiogenic effects are due to its impact on the BMP or VEGF signals through the development of analogues that target BMP but not VEGF signaling and vice versa. In a structure-activity relationship (SAR) study of dorsomorphin analogues based primarily on their effects on live zebrafish embryos, we identified highly selective and potent BMP inhibitors as well as selective VEGF inhibitors. One of the BMP inhibitors, DMH1, which exclusively targets the BMP but not the VEGF pathway, dorsalized the embryonic axis without disrupting the angiogenic process, demonstrating that BMP signaling was not involved in the angiogenic process. This is one of the first full-scale SAR studies performed in vertebrates and demonstrates the potential of zebrafish as an attractive complementary platform for drug development that incorporates an assessment of in vivo bioactivity and selectivity in the context of a living organism.

AB - The therapeutic potential of small molecule signaling inhibitors is often limited by off-target effects. Recently, in a screen for compounds that perturb the zebrafish embryonic dorsoventral axis, we identified dorsomorphin, the first selective inhibitor of bone morphogenetic protein (BMP) signaling. Here we show that dorsomorphin has significant "off-target" effects against the VEGF (vascular endothelial growth factor) type-2 receptor (Flk1/KDR) and disrupts zebrafish angiogenesis. Since both BMP and VEGF signals are known to be involved in vascular development, we sought to determine whether dorsomorphin's antiangiogenic effects are due to its impact on the BMP or VEGF signals through the development of analogues that target BMP but not VEGF signaling and vice versa. In a structure-activity relationship (SAR) study of dorsomorphin analogues based primarily on their effects on live zebrafish embryos, we identified highly selective and potent BMP inhibitors as well as selective VEGF inhibitors. One of the BMP inhibitors, DMH1, which exclusively targets the BMP but not the VEGF pathway, dorsalized the embryonic axis without disrupting the angiogenic process, demonstrating that BMP signaling was not involved in the angiogenic process. This is one of the first full-scale SAR studies performed in vertebrates and demonstrates the potential of zebrafish as an attractive complementary platform for drug development that incorporates an assessment of in vivo bioactivity and selectivity in the context of a living organism.

UR - http://www.scopus.com/inward/record.url?scp=77449108244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77449108244&partnerID=8YFLogxK

U2 - 10.1021/cb9002865

DO - 10.1021/cb9002865

M3 - Article

C2 - 20020776

AN - SCOPUS:77449108244

VL - 5

SP - 245

EP - 253

JO - ACS Chemical Biology

JF - ACS Chemical Biology

SN - 1554-8929

IS - 2

ER -